Primary outcome· 21 weeks
Basal and PMA-stimulated O2 Production Detected by Ferricytochrome c Reduction in Neutrophils
| Group | Value |
|---|---|
| gp91 CGD With HIGH Baseline Superoxide | not posted |
| Autosomal Recessive CGD With p47 | not posted |
Trial · Interventional
TerminatedPhase 4Results postedRegistry dataBiochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease
This trial was stopped early.
Reason given at the registry: Early termination due to only 2 subjects completing trial.
Results were posted for this trial.
This trial does not test a peptide that PepBank tracks.
- Names NAD+ (nicotinamide adenine dinucleotide), does not test it. It appears in the conditions.
Overview
- Status
- Terminated
- Phase
- Phase 4
- Enrollment
- 2 participants (actual)
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID) · Nih
- Design
- Not randomized · Open label (no masking)
- Countries
1 country
United States
- Start
- 18 May 2010
- Primary completion
- 14 Nov 2014
- Completion
- 14 Nov 2014
- First posted
- 22 Jun 2010 (estimated)
- Last update posted
- 20 Sept 2017
- Conditions
- IFN-Gamma Therapy · CGD Gene Mutation · CGD Response to IFNg · CGD - Chronic Granulomatous Disease · Immunodeficiency Disease
Timeline
1 trial · 1 stopped early · 1 with posted results
- Completed
- Ongoing
- Not yet recruiting
- Stopped
- Estimated dates (est.)
- Results posted
201020112012201320142015
- Ph 4Terminated
Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease
NCT0114704218 May 2010 to 14 Nov 2014
Registry summary
Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.
Background: \- Chronic granulomatous disease (CGD) is an immunodeficiency disease in which white blood cells are unable to kill certain bacteria and fungi. People with CGD are more likely to develop recurrent life-threatening infections. Certain changes or mutations in genes contribute to the severity of CGD, and also appear to affect the success of treatment with interferon-gamma, a substance that is used to improve the immune system s ability to fight infection. Researchers are interested in studying changes in the immune system caused by interferon-gamma treatment of CGD in individuals with different mutations that cause CGD. Objectives: \- To compare changes in the immune system caused by interferon-gamma treatment for CGD in individuals with different mutations that cause CGD. Eligibility: \- Individuals of any age who have been diagnosed with CGD and have specific types of mutations that cause CGD (to be determined after testing). Design: * Participants will be screened with a medical history, physical examination, and blood and urine tests. Participants must weigh more than 11 kilograms (\~24 pounds) to participate in the study. * Participants will receive injections of interferon-gamma once weekly for 4 weeks, twice weekly for 4 weeks, and then three times weekly for 4 weeks (a total of 24 injections). * Blood will be drawn periodically during treatment and for 8 weeks after the treatment, for a total of 21 weeks on the study. Participants will regularly provide information on their symptoms and responses to treatment to the study researchers.
Interventions
- IFN-gammaDrug
Arms2
Active comparator
gp91 CGD with relatively high baseline superoxide
Patients with X-linked Chronic Granulomatous Disease (CGD) with a missense gp91phox mutation and relatively high baseline superoxide production. IFN-gamma was the administered intervention.
Active comparator
Autosomal Recessive CGD with p47
Patients with Autosomal Recessive Chronic Granulomatous Disease (CGD) with p47 phox mutation. IFN-gamma was the administered intervention.
Primary outcomes1
Outcomes the sponsor listed as primary.
Basal and PMA-stimulated O2 Production Detected by Ferricytochrome c Reduction in Neutrophils
Time frame · 21 weeks
Posted results
Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.
Primary outcome results
Adverse events, as posted
| Group | Deaths | Serious events | Other events |
|---|---|---|---|
| gp91 CGD With Relatively High Baseline SuperoxidePatients with X-linked Chronic Granulomatous Disease (CGD) with a missense gp91phox mutation and relatively high baseline superoxide production | 0 / 2 | 0 / 2 | 0 / 2 |
Each cell reads participants affected / participants at risk, as the registry posted them.
Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works
Studies0
Studies that cite this trial.
No study cites this trial.
Eligibility
Who could join, as posted.
- Sex
- All
- Age
- Not stated
- Healthy volunteers
- Not accepted
Inclusion and exclusion criteria, as posted
* INCLUSION CRITERIA:
Subjects may be enrolled if they are:
1. Already are enrolled on an existing CGD protocol at the Clinical Center (and will remain enrolled on their existing protocol);
2. Are included in one of the study cohorts listed below;
3. Male or female;
4. Able to comply with self-administration of a subcutaneous injection; and
5. Willing to have their blood samples stored for the duration of this study and for future research.
Study Groups/Cohorts:
X-linked CGD Nonsense/Frameshift/RNA Processing/Deletion Mutations Cohort: Subjects in this cohort must have X-linked CGD resulting from a documented nonsense, frameshift, RNA processing, or deletion gene mutation. Subjects with other gene defects or for whom the specific genetic defect has not been determined are not eligible for inclusion in this cohort.
X-linked CGD Missense Mutation with Low Baseline Superoxide Production (less than or equal to 2.5 nmol/10(6) cells/hr) Cohort: Subjects in this cohort must have X-linked CGD resulting from a documented missense gene and superoxide production by cytochrome c reduction assay at baseline of less than or equal to 2.5 nmol/10(6) cells/hr. Subjects with other gene defects or for whom the specific genetic defect has not been determined are not eligible for inclusion in this cohort.
X-linked CGD Missense Mutation with Higher Baseline Superoxide Production (greater than 2.5 nmol/10(6) cells/hr) Cohort: Subjects in this cohort must have X-linked CGD resulting from a documented missense gene and superoxide production by cytochrome c reduction assay at baseline of greater than 2.5 nmol/10(6) cells/hr. Subjects with other gene defects or for whom the specific genetic defect has not been determined are not eligible for inclusion in this cohort.
Autosomal Recessive p47phox CGD Cohort: Subjects in this cohort must have autosomal recessive CGD resulting from a documented p47phox gene mutation. Subjects with other gene defects or for whom the specific genetic defect has not been determined are not eligible for inclusion in this cohort.
Autosomal Recessive p67phox CGD Cohort: Subjects in this cohort must have autosomal recessive CGD resulting from a documented p67phox gene mutation. Subjects with other gene defects or for whom the specific genetic defect has not been determined are not eligible for inclusion in this cohort.
EXCLUSION CRITERIA:
Subjects are excluded from the study who:
1. Have undergone successful bone marrow transplantation;
2. Had a serious adverse reaction to IFN gamma in the past;
3. Are pregnant or breast feeding;
4. Weigh less than 11 kg;
5. Are currently on therapy with INF gamma;
6. Have any of the following medical conditions:
* Coronary artery disease;
* Hepatic disease and/or liver enzymes elevated above 3 times normal;
* Seizure disorder, or
* Severe myelosuppression (absolute neutrophil count less than1000 cells/mm(3)).
Participation of Minors: minor patients will be invited to participant in this study.
Participation of Women: Exposure to IFN gamma by the developing human fetus may be detrimental. For this reason, women of childbearing-age will have a pregnancy test prior to undergoing study procedures. Should a woman become pregnant or suspect that she is pregnant while participating in this study, she should immediately inform study staff and her primary care physician.
Pregnancy and Lactation: The effects of IFN gamma therapy on the developing fetus and newborn infant have not been studied. Therefore, it is not recommended that subjects who are pregnant or breast-feeding receive IFN gamma and they will be excluded from this study.
PepBank is a research reference. Talk to a doctor before you use any peptide.